Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Dose Ranging, Parallel Group, Active (Spiriva® Respimat®) And Placebo Controlled Study To Assess Relative Bioavailability, Pharmacodynamics And Safety Of Three Doses Of Tiotropium Bromide Inhalation Solution In Subjects With Mild To Moderate Chronic Obstructive Pulmonary Disease

NCT03118765 is registered in ClinicalTrials.gov with Glenmark Specialty S.A. as lead sponsor.

NCT NCT03118765
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03118765 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Dose Ranging, Parallel Group, Active (Spiriva® Respimat®) And Placebo Controlled Study To Assess Relative Bioavailability, Pharmacodynamics And Safety Of Three Doses Of Tiotropium Bromide Inhalation Solution In Subjects With Mild To Moderate Chronic Obstructive Pulmonary Disease
Lead sponsor
Glenmark Specialty S.A.
Phase
Phase 2
Overall status
Completed
Start date
March 24, 2017
Completion date
July 31, 2017
Enrollment
155 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

mild to moderate chronic obstructive pulmonary disease (copd)